<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients&apos; Quality of Life: a Prospective, Non-interventional Trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-11-21">November 21, 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Martin</forename><surname>Metz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Weller</forename><surname>Karsten</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Neumeister</forename><surname>Claudia</surname></persName>
						</author>
						<author>
							<persName><surname>In</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Izquierdo</forename><surname>Rolf-Hasso</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bo</forename><forename type="middle">¨deker</forename><surname>Ulrich</surname></persName>
						</author>
						<author role="corresp">
							<persName><forename type="first">Schwantes</forename><forename type="middle">Marcus</forename><surname>Maurer</surname></persName>
							<email>ulrich.schwantes@dr-pfleger.de</email>
						</author>
						<author>
							<persName><forename type="first">Á</forename><forename type="middle">K</forename><surname>Weller</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Á</forename><forename type="middle">M</forename><surname>Maurer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Neumeister</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Á</forename><forename type="middle">U</forename><surname>Schwantes</surname></persName>
						</author>
						<author>
							<persName><forename type="first">I</forename><surname>Izquierdo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Rolf-Hassobo</forename><surname>¨deker</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">R</forename><surname>Pfleger</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<orgName type="institution" key="instit1">Allergy-Centre-Charite ´</orgName>
								<orgName type="institution" key="instit2">Charite ´-University Hospital Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Department of Medical Science/Clinical Research</orgName>
								<orgName type="institution">Dr. R. Pfleger GmbH</orgName>
								<address>
									<settlement>Bamberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Department of Clinical Research</orgName>
								<orgName type="institution">Uriach Group</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Statistics</orgName>
								<orgName type="department" key="dep2">Institute for Medical Informatics</orgName>
								<orgName type="institution">University Clinic Giessen</orgName>
								<address>
									<settlement>Giessen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients&apos; Quality of Life: a Prospective, Non-interventional Trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-11-21">November 21, 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">D792151F59BA47CB7C0AFA73370B3ADE</idno>
					<idno type="DOI">10.1007/s13555-015-0089-y</idno>
					<note type="submission">Received: October 12, 2015 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:51+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Angioedema</term>
					<term>Chronic spontaneous urticaria (CSU)</term>
					<term>Chronic urticaria questionnaire on quality of life (CU-Q 2 oL)</term>
					<term>Non-interventional study</term>
					<term>Quality of life (QoL)</term>
					<term>Rupatadine</term>
					<term>Urticaria activity score (UAS7)</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Introduction: Chronic spontaneous urticaria (CSU) is a common and hard to treat condition associated with a substantial negative impact on patients' quality of life (QoL).</s><s>Clinical studies have shown that rupatadine is effective and safe in the treatment of CSU, but data from routine clinical care are scarce.</s><s>Therefore, we assessed the effectiveness and tolerability of rupatadine in established dosages on CSU activity and patients' QoL in a routine daily practice setting.</s><s>Methods: This was an open, prospective, non-interventional study performed in 146 dermatological practices in Germany.</s><s>CSU patients for whom treatment with rupatadine was indicated were eligible to participate.</s><s>Key symptoms of urticaria activity and their impact on patients' QoL were assessed at the beginning and the end of treatment.</s><s>Adverse events (AEs) and withdrawals, as well as the dosage regimens chosen, were documented.</s><s>Patients and physicians were requested to rate effectiveness and tolerability of therapy at the final visit.</s><s>All statistical analyses were descriptive.</s><s>Results: The majority of the 660 patients screened to be treated (median age 44 years, IQR = 31-59 years, n = 654) received rupatadine 10 mg tablets once (477 patients) or twice (105 patients) daily for a median time of 28 days.</s><s>After treatment, 93.2% of the patients (606/650) reported a clear overall improvement of symptoms.</s><s>Rupatadine significantly reduced the urticaria activity score (UAS7) as well as the frequency and severity of existing angioedema episodes.</s><s>Similarly all domains of the urticaria-specific</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Chronic spontaneous urticaria (CSU) is one of the most common and disturbing cutaneous conditions.</s><s>CSU is characterized by the daily or almost daily reoccurrence of pruritic wheals, angioedema, or both, for more than 6 weeks <ref type="bibr" target="#b7">[1]</ref>.</s><s>In the majority of cases, the underlying cause remains unidentified <ref type="bibr" target="#b7">[1,</ref><ref type="bibr" target="#b8">2]</ref>.</s><s>The condition often lasts for years <ref type="bibr" target="#b7">[1,</ref><ref type="bibr" target="#b8">2]</ref>.</s><s>Besides being bothersome and debilitating, CSU has a proven substantial negative impact on quality of life (QoL) of affected individuals <ref type="bibr" target="#b8">[2]</ref><ref type="bibr" target="#b9">[3]</ref><ref type="bibr" target="#b10">[4]</ref><ref type="bibr" target="#b11">[5]</ref><ref type="bibr" target="#b12">[6]</ref><ref type="bibr" target="#b13">[7]</ref>.</s><s>Treatment, which is almost always provided on an outpatient basis, is still a challenge.</s><s>The first line treatment of CSU, according to the recommendations of the current EAACI/GA 2 LEN/EDF/WAO urticaria guideline <ref type="bibr" target="#b7">[1]</ref>, is the continued use of non-sedating, second-generation antihistamines (nsAHs).</s><s>These drugs have been shown to be efficacious and safe in numerous clinical trials, but real-life data from the use of these drugs in routine clinical care are limited.</s><s>This is especially true for newer nsAHs such as rupatadine.</s></p><p><s>Rupatadine, an N-alkyl pyridine derivative, is a selective oral histamine H 1 -receptor inverse agonist, indicated for symptomatic treatment of allergic rhinitis and urticaria in adults and children C2 years <ref type="bibr" target="#b14">[8,</ref><ref type="bibr" target="#b15">9]</ref>.</s><s>The drug exhibits strong and balanced antagonist activities towards both histamine H 1 -and platelet-activating factor (PAF) receptors (for review see: <ref type="bibr" target="#b16">[10]</ref><ref type="bibr" target="#b17">[11]</ref><ref type="bibr" target="#b18">[12]</ref><ref type="bibr" target="#b19">[13]</ref><ref type="bibr" target="#b20">[14]</ref><ref type="bibr" target="#b21">[15]</ref><ref type="bibr" target="#b22">[16]</ref>).</s><s>Both histamine and PAF are held to importantly contribute to the signs and symptoms of CSU, i.e., itchy wheals and angioedema <ref type="bibr" target="#b23">[17]</ref>.</s><s>Moreover, rupatadine has a broad profile of anti-inflammatory effects by inhibiting both inflammatory cells and a range of mediators involved in the early-and late-phase inflammatory responses <ref type="bibr" target="#b16">[10,</ref><ref type="bibr" target="#b24">18,</ref><ref type="bibr" target="#b25">19]</ref>.</s><s>After oral administration, rupatadine shows a fast onset of action, producing rapid symptomatic relief, and a long-lasting ([24 h) clinical activity, which allows administration once a day <ref type="bibr" target="#b18">[12,</ref><ref type="bibr" target="#b26">20]</ref>.</s><s>Rupatadine has undergone long-term testing (up to 1 year) in compliance with ICH and EMA guidelines confirming its good safety profile <ref type="bibr" target="#b27">[21]</ref><ref type="bibr" target="#b28">[22]</ref><ref type="bibr" target="#b29">[23]</ref>.</s><s>At the licensed daily oral dose of 10 mg, rupatadine has no clinically relevant effects on the cardiovascular system, cognitive function or psychomotor function <ref type="bibr" target="#b16">[10,</ref><ref type="bibr" target="#b20">14]</ref>.</s><s>The current guideline on the management of urticaria patients recommends aiming for a complete symptom relief <ref type="bibr" target="#b7">[1]</ref>.</s><s>However, many patients fail to get satisfactory relief with the licensed doses <ref type="bibr" target="#b7">[1,</ref><ref type="bibr" target="#b8">2]</ref>.</s><s>In this case, the European guideline advises to progressively increase the conventional dosages of oral nsAHs up to fourfold in poorly responding patients <ref type="bibr" target="#b7">[1]</ref>.</s><s>In fact, higher doses of antihistamines are very common in general practice and in clinical studies and do show benefits for individual patients <ref type="bibr" target="#b7">[1,</ref><ref type="bibr" target="#b8">2,</ref><ref type="bibr" target="#b27">21,</ref><ref type="bibr" target="#b30">24]</ref>.</s><s>However, there is little information on the use, the effects and safety of rupatadine in CSU treatment outside of RCTs neither for the approved nor for higher than standard doses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Design</head><p><s>This multicenter, open, prospective, non-interventional, observational trial was conducted by 146 dermatologists in private practices in Germany from April 1, 2011 until June 30, 2011 (last day of recruitment).</s><s>The rupatadine therapy was prescribed by the participating physicians in the course of normal outpatient care, was commercially available and funded according to local practice in usual routine care.</s><s>The study protocol, therefore, did not contain any specifications regarding dosing of rupatadine or duration of treatment.</s><s>Instead, the advising dermatologists were asked to follow the recommendations defined in the licensed approval from the national regulatory authorities.</s><s>The contraindications, special warnings and precautions for use, interactions, information on use during pregnancy and lactation, effects on ability to drive and use machines, and desirable effects specified in the Summary of Product Characteristics (SmPC) had to be observed.</s><s>Prior to the start of this study, all participating physicians were instructed in the conduct and documentation of the trial.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Compliance with Ethics</head><p><s>This non-interventional, observational trial conformed with § 67 <ref type="bibr" target="#b12">(6)</ref>  GmbH, Bamberg, Germany, <ref type="bibr" target="#b14">[8]</ref>) was prescribed by the attending physician, were eligible to enter the trial.</s><s>Any current and prior medications were acceptable for their inclusion.</s><s>Participants were free to withdraw at will at any time.</s><s>If they were or decided to withdraw from the study, the reason for discontinuation had to be specified.</s></p><p><s>The sample size of this trial was formed through the number of patients that were treated during the predetermined study period by any of the participating dermatologists.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessments and Outcome Measures</head><p><s>There were no defined study-related procedures; and the angioedema score.</s></p><formula xml:id="formula_0">measurements</formula><p><s>Additionally, at the initial and final visit, the patients were asked to fill in the German version of the validated Chronic Urticaria Quality of Life Questionnaire (CU-Q 2 oL) <ref type="bibr" target="#b9">[3,</ref><ref type="bibr" target="#b12">6]</ref> to assess the impact of the disease on their quality of life.</s><s>The German CU-Q 2 oL measures health-related QoL in 6 domains (functioning, sleep, itching/ embarrassment, mental status, swelling/eating, and limits looks) and comprises 23 items evaluating the answers on a five-level Likert scale.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Management and Statistics</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Trial Population and Patient Baseline Characteristics</head><p><s>The data of all 660 participants included in this study were entered into the safety analysis.</s></p><p><s>According to the observational plan, one patient was excluded from the evaluation of efficacy due to a treatment period of less than</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Global Assessment of Effectiveness and Tolerability</head><p><s>According to the observational study protocol, the data of 651 patients/physicians were considered relevant for overall assessment of treatment effectiveness. Figure <ref type="figure" target="#fig_5">3a</ref> depicts the results of this rating as recorded by the physicians and patients at the final visit.</s><s>Most of the dermatologists (558/643, 86.8%) rated therapy outcome as complete response (328/643) or as significantly improved (230/643), compared with 4.5% (29/643) of the physicians who assessed symptom severity to be unchanged (26/643) or worse (3/643).</s><s>The patient ratings of the global efficacy of treatment with rupatadine followed similar trends, with only 1.8% (12/648) of patients rated effectiveness of therapy to be poor.</s><s>Similarly, a significantly greater number of patients (622/648, 96%) assessed treatment outcome as very good (477/ 648) or good (145/648).</s><s>Tolerability of rupatadine treatment was rated as very good or good by 87.8% (572/651) of the physicians and by 95.7% (620/648) of the patients (Fig. <ref type="figure" target="#fig_5">3b</ref>).</s></p><p><s>The question relating to therapy continuation with rupatadine was answered affirmatively for 367 out of 648 patients (56.6%) and negated for 276 patients (42.6%) by the physicians after the observational period.</s></p><p><s>The standard recommended daily dose of 10 mg of rupatadine was the most frequently prescribed dosage (271/367, 73.8%).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Therapy Withdrawals and Adverse Events</head><p><s>Treatment with rupatadine was prematurely terminated in 39 of 660 (5.9%) patients.</s></p><p><s>Reasons for withdrawal were lack of efficacy (20/ 39), AEs (7/39) and ''other'' (6/39) including 5</s></p><p><s>cases of nonattendance at the final visit, or not drug related (4/39); for 2 patients respective information was missing.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>To our knowledge this is the first observational, non-interventional study to demonstrate the effectiveness and favorable tolerability of oral rupatadine administered according to the established dosage recommendations in the treatment of CSU in routine outpatient care.</s></p><p><s>As CSU has a detrimental effect on both objective functioning and subjective well-being <ref type="bibr" target="#b7">[1,</ref><ref type="bibr" target="#b8">2,</ref><ref type="bibr" target="#b10">[4]</ref><ref type="bibr" target="#b11">[5]</ref><ref type="bibr" target="#b12">[6]</ref><ref type="bibr" target="#b13">[7]</ref><ref type="bibr" target="#b16">10]</ref>, evaluation of urticaria activity is just as important to be looked at as assessment of the impact of the on patients' QoL.</s></p><p><s>Therefore, two validated and tools for patient-reported outcomes assessment were used in the present study: the UAS7 score for symptoms and the Cu-Q 2 oL questionnaire for urticaria-related QoL impairment.</s><s>Noting the changes in frequency and severity of itchy wheals as well as of angioedema episodes is a useful way of evaluating clinical efficacy <ref type="bibr" target="#b7">[1]</ref>.</s></p><p><s>The relevant differences in CSU activity, observed in the present trial after a median treatment period of 28 days and determined through the use of the UAS7 and the angioedema score, indicated that an oral dose of 10 mg rupatadine, administered once or twice daily, produced obvious improvements in the clinical status of the affected patients.</s></p><p><s>These results are in line with the clinical evaluations, on which approval for the drug was granted.</s><s>The efficacy of rupatadine in the treatment of moderate-to-severe CSU was evaluated in two randomized, double-blind, placebo-controlled multicentre studies <ref type="bibr" target="#b32">[26,</ref><ref type="bibr" target="#b33">27]</ref>.</s><s>Both trials showed that rupatadine 10 mg and 20 mg per day rapidly and significantly reduced urticaria symptoms and improved health-related QoL of these patients.</s><s>A pooled responder analysis of both studies highlighted the greater improvements when using the higher dosage of 20 mg rupatadine daily <ref type="bibr" target="#b30">[24]</ref>: evaluating disease activity by use of the UAS a significant reduction of at least 75% in the 10 mg (34.8%) and 20 mg (48%) rupatadine groups as compared to 13.9% in the placebo group (p\0.0001) was demonstrated.</s><s>In the The majority of the patients in our study (77.9%) were using the approved (standard) dose of the drug (10 mg of rupatadine once daily) which is defined in the current SmPC <ref type="bibr" target="#b14">[8]</ref>.</s><s>Based on the favorable effectiveness in the present study, the responder rates to rupatadine treatment under real-life conditions might be higher than those expected for nsAHs.</s></p><p><s>A systematic review of responder rates reported in RCTs indicated that H (percentages of AEs according to <ref type="bibr" target="#b14">[8]</ref>).</s><s>The majority of AEs related to rupatadine were of mild or moderate severity and their incidence has been similar to those of active comparators or placebo.</s><s>The good tolerability of rupatadine was confirmed in various long-term safety studies as well <ref type="bibr" target="#b27">[21]</ref><ref type="bibr" target="#b28">[22]</ref><ref type="bibr" target="#b29">[23]</ref>.</s><s>Most importantly, rupatadine has been shown to have no effects on CNS activity, on objective psychomotor tasks or on subjective evaluations <ref type="bibr" target="#b37">[31]</ref><ref type="bibr" target="#b38">[32]</ref><ref type="bibr" target="#b39">[33]</ref><ref type="bibr" target="#b40">[34]</ref>, and has no cardiotoxic effects <ref type="bibr" target="#b41">[35]</ref>.</s><s>In two clinical studies, it has been demonstrated that the drug displays unwanted CNS side activities only at the highest evaluated dose of 80 mg, while therapeutically relevant lower doses (20 and 10 mg) were similar to placebo <ref type="bibr" target="#b37">[31,</ref><ref type="bibr" target="#b42">36]</ref></s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Data were entered into a data base (MS ACCESS 2003) via single entry.</s><s>The validity of data was checked (a) by plausibility checks within the data base and (b) by a comparison of all data with the data in 5% of all CRFs.</s><s>Data were analyzed by the statistical program SPSS 10.0 (IBM Corporation, NY, USA) solely in an exploratory sense.</s><s>Descriptive statistics were used to report the results.</s><s>Analyses of all variables, including effectiveness and tolerability outcomes, were performed using any participant entered into the study who had the data relevant to that analysis.</s><s>Distribution of each variable is presented by median, minimum, maximum, and interquartile range (IQR).</s><s>As normal distribution of the parameters of interest could not be assumed, change from baseline UAS7 score and CU-Q 2 oL was analyzed using the Wilcoxon signed rank test.</s><s>The given computed p values for the observed or a more extreme result were p\0.001; the p values are only a measure of the reproducibility of the observed results.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>. The median time to change of symptoms was specified at 4 days (min = 1 day, max = 40 days, n = 594).</s><s>Evaluating disease activity by use of the UAS7, rupatadine significantly reduced number of wheals and pruritus severity from a median value of 25.0 (min = 2.0, max = 42.0,</s><s>IQR 18.0-30.0,</s><s>n = 632) before treatment to 7.0 (min = 0, max = 42.0,</s><s>IQR 2.0-14.0,</s><s>n = 632) post-treatment (Fig. 1).</s><s>The change from baseline in these key symptoms of CSU over the treatment period is in median 15.5 (min = -23.0,</s><s>max = 42.0,</s><s>IQR 9.0-22.0,</s><s>n = 622, p Wilcoxon signed rank test \0.001).</s><s>Under treatment with either 10 or 20 mg rupatadine per day, improvements in the frequency and severity/size of an angioedema were observed.</s><s>At the final visit, 81 (60.9%) out of the initial affected patients showed a complete response (i.e., no angioedema) and 42 patients (31.6%) reported clinically meaningful improvements in the occurrence and severity of episodes as documented by the angioedema score; three patients reported worsening of the still existing angioedema and nine patients reported new development of an angioedema.</s><s>Before rupatadine treatment, CSU patients showed major impairment of overall disease-related QoL (Fig. 2) as well as in all domains of QoL including sleep, itching/ embarrassment and mental status as measured by the Cu-Q 2 oL (Table 1).</s><s>Under rupatadine treatment QoL of CSU patients improved with reductions in all six domains of the questionnaire from baseline, even in the items I (functioning) and VI (limits looks).</s><s>Regarding the median change in total Cu-Q 2 oL score of 23.91 (min = -48.91,</s><s>max = 88.04,</s><s>IQR = 13.04-36.96,</s><s>n = 551), there was an indication of an important change (p Wilcoxon signed rank test \0.001).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Overall, 21</head><label>21</label><figDesc><div><p><s>out of the 660 (3.2%) patients experienced 27 AEs during rupatadine treatment.</s><s>The most frequently reported AEs with an at least possible causal relationship were fatigue (n = 11), headache (n = 3) and nausea (n = 3).</s><s>Treatment with the study drug was discontinued in 11 out of the 21 patients with an AE, and in 10 cases medication was maintained.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 UAS7 score before and after treatment with rupatadine (n = 622).</s><s>The bottom and the top of each notched box are the first and third quartiles, and the line inside the box is the median.</s><s>The whiskers represent the lowest extreme value limit still within 1.5 9 IQR subtracted from the lower quartile, and the upper extreme value limit still within 1.5 9 IQR added to the upper quartile.</s><s>Stars mark extreme values which are either</s></p></div></figDesc><graphic coords="7,106.33,77.95,368.64,274.56" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. 2</head><label>2</label><figDesc><div><p><s>Fig. 2 CU-Q 2 oL total score before and after treatment with rupatadine (n = 521).</s><s>The unfilled circles indicate outliers which are either 3 9 IQR or more above the third quartile or 3 9 IQR or more below the first quartile.</s><s>The</s></p></div></figDesc><graphic coords="8,120.50,77.53,368.64,277.92" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>BFig. 3</head><label>3</label><figDesc><div><p><s>Fig. 3 Physicians' and patients' global assessment of treatment effectiveness a and tolerability b of rupatadine 10 mg tablets, once or twice daily, at the end of treatment</s></p></div></figDesc><graphic coords="10,161.92,354.23,237.27,158.95" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>of the German Drug Law.</s><s>Accordingly, the competent authorities,</s></p></div></figDesc><table><row><cell cols="7">National Association of Statutory Health</cell></row><row><cell cols="2">Insurance</cell><cell cols="2">Physicians,</cell><cell>and</cell><cell>the</cell><cell>central</cell></row><row><cell cols="7">association of health insurers were given</cell></row><row><cell cols="7">notice of the study. Approval of an ethical</cell></row><row><cell cols="7">committee was not required for such a</cell></row><row><cell cols="7">non-interventional post-registration trial in</cell></row><row><cell cols="7">Germany. Nevertheless, the study protocol was</cell></row><row><cell cols="7">submitted to the independent Freiburger Ethics</cell></row><row><cell cols="7">Committee, Freiburg, Germany, who gave a</cell></row><row><cell cols="7">favorable recommendation prior to the start of</cell></row><row><cell cols="7">the study (February 2011). All procedures were</cell></row><row><cell cols="7">carried out according to the established</cell></row><row><cell cols="7">regulations and official recommendations of</cell></row><row><cell cols="7">the Federal Institute for Drugs and Medical</cell></row><row><cell cols="7">Devices (BfArM) and the Paul-Ehrlich-Institute</cell></row><row><cell>(PEI)</cell><cell cols="2">relating</cell><cell>to</cell><cell>the</cell><cell cols="2">conduct</cell><cell>of</cell></row><row><cell cols="7">non-interventional trials [25]. This study was</cell></row><row><cell cols="7">performed within the indication approved in</cell></row><row><cell cols="7">the marketing authorization and under</cell></row><row><cell cols="7">consideration of the contraindications and</cell></row><row><cell cols="7">precautions defined there. Informed consent</cell></row><row><cell cols="7">regarding data protection was obtained from all</cell></row><row><cell cols="7">patients before being included in the study.</cell></row><row><cell>Patients</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="7">All outpatients with a confirmed diagnosis of</cell></row><row><cell>CSU,</cell><cell>for</cell><cell cols="2">whom</cell><cell cols="2">treatment</cell><cell>with</cell><cell>a</cell></row><row><cell cols="3">second-generation</cell><cell cols="4">H 1 -antihistamine</cell><cell>was</cell></row><row><cell cols="7">indicated and a rupatadine preparation</cell></row><row><cell cols="7">containing 10 mg active agent per tablet (e.g.,</cell></row><row><cell cols="7">Urtimed Ò 10 mg Tabletten, Dr. R. Pfleger</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 1</head><label>1</label><figDesc><div><p><s>Disease-specific quality of life impairment as assessed by the CU-Q 2 oL questionnaire before and at the end of treatment with rupatadine 10 mg tablets, once or twice daily</s></p></div></figDesc><table><row><cell>Item</cell><cell>N</cell><cell>Minimum</cell><cell>Lower quartile</cell><cell>Median</cell><cell>Upper quartile</cell><cell>Maximum</cell></row><row><cell>Functioning</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Before treatment</cell><cell>597</cell><cell>0.00</cell><cell>29.17</cell><cell>45.83</cell><cell>58.33</cell><cell>100.00</cell></row><row><cell>After treatment</cell><cell>597</cell><cell>0.00</cell><cell>0.00</cell><cell>12.50</cell><cell>25.00</cell><cell>100.00</cell></row><row><cell>Difference a</cell><cell>597</cell><cell>-54.17</cell><cell>12.50</cell><cell>25.00</cell><cell>41.67</cell><cell>91.67</cell></row><row><cell>Sleep</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Before treatment</cell><cell>619</cell><cell>0.00</cell><cell>31.25</cell><cell>50.00</cell><cell>68.75</cell><cell>100.00</cell></row><row><cell>After treatment</cell><cell>619</cell><cell>0.00</cell><cell>6.25</cell><cell>18.75</cell><cell>37.50</cell><cell>100.00</cell></row><row><cell>Difference a</cell><cell>619</cell><cell>-62.50</cell><cell>12.50</cell><cell>25.00</cell><cell>43.75</cell><cell>100.00</cell></row><row><cell>Itching/embarrassment</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Before treatment</cell><cell>617</cell><cell>0.00</cell><cell>43.75</cell><cell>56.25</cell><cell>68.75</cell><cell>100.00</cell></row><row><cell>After treatment</cell><cell>617</cell><cell>0.00</cell><cell>6.25</cell><cell>18.75</cell><cell>31.25</cell><cell>100.00</cell></row><row><cell>Difference a</cell><cell>617</cell><cell>-31.25</cell><cell>18.75</cell><cell>37.50</cell><cell>50.00</cell><cell>93.75</cell></row><row><cell>Swelling/eating</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Before treatment</cell><cell>604</cell><cell>0.00</cell><cell>6.25</cell><cell>18.75</cell><cell>37.50</cell><cell>87.50</cell></row><row><cell>After treatment</cell><cell>604</cell><cell>0.00</cell><cell>0.00</cell><cell>6.25</cell><cell>12.50</cell><cell>93.75</cell></row><row><cell>Difference a</cell><cell>604</cell><cell>-81.25</cell><cell>0.00</cell><cell>6.25</cell><cell>18.75</cell><cell>87.50</cell></row><row><cell>Mental status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Before treatment</cell><cell>628</cell><cell>0.00</cell><cell>25.00</cell><cell>41.67</cell><cell>66.67</cell><cell>100.00</cell></row><row><cell>After treatment</cell><cell>628</cell><cell>0.00</cell><cell>0.00</cell><cell>16.67</cell><cell>33.33</cell><cell>100.00</cell></row><row><cell>Difference a</cell><cell>628</cell><cell>-50.00</cell><cell>8.33</cell><cell>25.00</cell><cell>41.67</cell><cell>100.00</cell></row><row><cell>Limits looks</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Before treatment</cell><cell>622</cell><cell>0.00</cell><cell>0.00</cell><cell>25.00</cell><cell>50.00</cell><cell>100.00</cell></row><row><cell>After treatment</cell><cell>622</cell><cell>0.00</cell><cell>0.00</cell><cell>0.00</cell><cell>25.00</cell><cell>100.00</cell></row><row><cell>Difference a</cell><cell>622</cell><cell>-75.00</cell><cell>0.00</cell><cell>12.50</cell><cell>25.00</cell><cell>100.00</cell></row><row><cell cols="3">CU-Q 2 oL urticaria-specific QoL questionnaire a Before treatment minus after treatment</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Dermatol Ther (Heidelb) (2015) 5:217-230</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>Sponsorship and article processing charges for this study were funded by Dr. R. Pfleger GmbH, Bamberg, Germany.</s><s>All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.</s></p><p><s>Editorial assistance in the preparation of this manuscript was provided by Dr. Petra Schwantes, BioMedical Services, Germany.</s><s>Support for this assistance was funded by Dr.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Compliance with ethics guidelines.</s><s>All procedures followed were in accordance with the ethical standards of the independent Freiburger Ethics Committee, with the German Drug Law, and with the joint recommendations of the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich-Institute relating to the conduct of non-interventional trials.</s><s>Informed consent regarding data protection was obtained from all patients before being included in the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Open</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><forename type="middle">M</forename><surname>Disclosures</surname></persName>
		</author>
		<author>
			<persName><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dr</forename><forename type="middle">R</forename><surname>Bayer</surname></persName>
		</author>
		<author>
			<persName><surname>Pfleger</surname></persName>
		</author>
		<author>
			<persName><surname>Gsk</surname></persName>
		</author>
		<author>
			<persName><surname>Leo</surname></persName>
		</author>
		<author>
			<persName><surname>Sanofi</surname></persName>
		</author>
		<author>
			<persName><surname>Shire</surname></persName>
		</author>
		<author>
			<persName><surname>Moxie</surname></persName>
		</author>
		<author>
			<persName><surname>Msd</surname></persName>
		</author>
		<author>
			<persName><surname>Novartis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Uriach</forename><surname>Ucb</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">is or recently was a speaker for Dr</title>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">In addition, he is or was involved in clinical research projects of Dr. R. Pfleger, Uriach, Essex pharma (now MSD), Novartis, Shire, and Vivopharma. C. Neumeister is employee (Senior Project Manager Clinical Research) of Dr</title>
		<author>
			<persName><forename type="first">R</forename><surname>Pfleger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ucb</forename><surname>Uriach</surname></persName>
		</author>
		<author>
			<persName><surname>Novartis</surname></persName>
		</author>
		<author>
			<persName><surname>Shire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Moxie</forename><surname>Vivopharma</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>R. Pfleger GmbH</note>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Izquierdo is executive employee (Head Clinical Development &amp; Medical Advice) of Uriach Group</title>
		<author>
			<persName><forename type="first">I</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main">Bo ¨deker is paid consultant (statistical planning and analysis) to Dr</title>
		<author>
			<persName><forename type="first">R.-H. ; R. Pfleger</forename><surname>Gmbh</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Schwantes is executive employee (Head of Medical Science/Clinical R esearch) of Dr</title>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Pfleger</forename><surname>Gmbh</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">is or recently was a Speaker and/or Advisor for and/or has received funding from FAES</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer ; Genentech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gsk</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Merckle</forename><surname>Recordati</surname></persName>
		</author>
		<author>
			<persName><surname>Novartis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">.</forename><forename type="middle">R</forename><surname>Dr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sanofi</forename><surname>Pfleger</surname></persName>
		</author>
		<author>
			<persName><surname>Aventis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ucb</forename><surname>Msd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Uriach</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Eaaci</forename><surname>Et The</surname></persName>
		</author>
		<author>
			<persName><surname>Ga2len</surname></persName>
		</author>
		<author>
			<persName><surname>Edf</surname></persName>
		</author>
		<idno type="DOI">10.1111/all.12313</idno>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Unmet clinical needs in chronic spontaneous urticaria. A Ga 2 LEN task force report 1</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="317" to="330" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The German version of the chronic urticaria quality-of-life questionnaire: factor analysis, validation, and initial clinical findings</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mlynek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hanna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="927" to="936" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Ortonne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJD</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="page" from="633" to="641" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">How to assess disease activity in patients with chronic urticaria</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mlynek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zalewska-Janowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="777" to="780" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q 2 oL)</title>
		<author>
			<persName><forename type="first">I</forename><surname>Baiardini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pasquali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Braido</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1073" to="1078" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a Ga 2 LEN taskforce position paper</title>
		<author>
			<persName><forename type="first">I</forename><surname>Baiardini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Braido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="840" to="844" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Urtimed Ò 10 mg Tabletten</title>
		<ptr target="http://www.fachinfo.de" />
	</analytic>
	<monogr>
		<title level="j">Dr. R. Pfleger GmbH</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Fachinformation (SmPC)</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Urtimed Ò 1 mg/ml Lo ¨sung</title>
		<ptr target="http://www.fachinfo.de" />
	</analytic>
	<monogr>
		<title level="j">Dr. R. Pfleger</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Fachinformation (SmPC)</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Update on rupatadine in the management of allergic disorders</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mullol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bachert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1" to="24" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Merlos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Giral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Balsa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page" from="114" to="121" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">A new selective histamine H 1 receptor and platelet-activating factor (PAF) antagonist</title>
		<author>
			<persName><forename type="first">I</forename><surname>Izquierdo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Merlos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Garcı ´a-Rafanell</surname></persName>
		</author>
		<author>
			<persName><surname>Rupatadine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs Today</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="451" to="468" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Rupatadine: pharmacological profile and its use in the treatment of allergic disorders</title>
		<author>
			<persName><forename type="first">C</forename><surname>Picado</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Pharmacother</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1989" to="2001" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">A review of its use in the management of allergic disorders</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Keam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Plosker</surname></persName>
		</author>
		<author>
			<persName><surname>Rupatadine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="457" to="474" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Rupatadine for the treatment of allergic rhinitis and urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="15" to="20" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Rupatadine for the treatment of urticaria</title>
		<author>
			<persName><forename type="first">E</forename><surname>Nettis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Donne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Di Leo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Calogiuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ferrannini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vacca</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Pharmacother</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="1807" to="1813" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gime ´nez-Arnau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Martinez-Escala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="256" to="258" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">In vitro inhibitory effect of rupatadine on histamine and TNF-a release from dispersed canine skin mast cells and the human mast cell line HMC-1</title>
		<author>
			<persName><forename type="first">M</forename><surname>Queralt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Brazı ´s</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Merlos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>De Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Puigdemont</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Inflamm Res</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="355" to="360" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli</title>
		<author>
			<persName><forename type="first">M</forename><surname>Vasiadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kalogeromitros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kempuraj</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Arch Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page" from="38" to="45" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Antihistaminic effects of rupatadine and PKPD modelling</title>
		<author>
			<persName><forename type="first">J</forename><surname>Pen ˜a</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Carbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Solans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nadal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Izquierdo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Merlos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Drug Metabol Pharmacokinet</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="107" to="116" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Scholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ferra ´n</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Izquierdo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gime ´nez-Arnau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="86" to="92" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Valero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>De La Torre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Castillo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Saf</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="33" to="42" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Gime ´nez-Arnau A. Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one-year study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Martinez-Escala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Curto-Barredo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Carnero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Pujol</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venerol</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="278" to="282" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gime ´nez-Arnau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Izquierdo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JEADV</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1088" to="1091" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<ptr target="http://www.bfarm.de/SharedDocs/Bekanntmachungen/DE/Arzneimittel/klinPr/bm-KlinPr-20100707-NichtinterventePr-pdf.pdf?__blob=publicationFile&amp;v=5" />
		<title level="m">Durchfu ¨hrung und Auswertung von Anwendungsbeobachtungen</title>
				<imprint>
			<date type="published" when="2011-01">Jan 2011</date>
		</imprint>
		<respStmt>
			<orgName>BfArM 2010. Empfehlungen des Bundesinstituts fu ¨r Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Dubertret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zalupca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cristodoulo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Dermatol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="223" to="228" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gime ´nez-Arnau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Pujol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ianosi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="539" to="546" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Dakhale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Shinde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Mahatme</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Dermatol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="643" to="649" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety</title>
		<author>
			<persName><forename type="first">R</forename><surname>Maiti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jaida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Raghavendra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Goud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Palani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Drugs Dermatol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1444" to="1450" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">A comparative study of efficacy and safety of rupatadine versus desloratadine in patients with chronic idiopathic urticaria</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Kolasani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mudium</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Reddy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Asian J Biomed Pharm Sci</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="42" to="47" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Barbanoj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garcı ´a-Gea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Morte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Izquierdo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Pe ´rez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jane</forename><surname>´f</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychobiology</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="311" to="321" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Barbanoj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garcı ´a-Gea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Antonijoan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Psychopharmacol Clin Exp</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="13" to="26" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers</title>
		<author>
			<persName><forename type="first">E</forename><surname>Vuurman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Theunissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van Oers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Van Leeuwen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jolles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Psychopharmacol Clin Exp</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="289" to="297" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Garcı ´a-Gea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Ballester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Martı ´nez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="663" to="674" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a´thorough QT/QTc study&apos; performed according to ICH guidelines</title>
		<author>
			<persName><forename type="first">E</forename><surname>Donado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Izquierdo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Pe ´rez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="401" to="410" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Efficacy and tolerability of rupatadine at four times the recommended dose against histamine-and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page" from="1330" to="1332" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
